Found: 20
Select item for more details and to access through your institution.
Dynamic contrast-enhanced MR imaging pharmacokinetic parameters as predictors of treatment response of brain metastases in patients with lung cancer.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Perception of Lung Cancer Risk: Impact of Smoking Status and Nicotine Dependence.
- Published in:
- Current Oncology Reports, 2018, v. 20, p. 1, doi. 10.1007/s11912-017-0650-1
- By:
- Publication type:
- Article
Real-life feasibility of home-based pulmonary rehabilitation in chemotherapy-treated patients with thoracic cancers: a pilot study.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Paclitaxel–bevacizumab combination in advanced non-squamous non-small-cell lung cancer (NSCLC): AVATAX, a retrospective multicentric study.
- Published in:
- Therapeutic Advances in Medical Oncology, 2022, p. 1, doi. 10.1177/17588359221099399
- By:
- Publication type:
- Article
A randomized, phase 2 study of deoxyuridine triphosphatase inhibitor, TAS-114, in combination with S-1 versus S-1 alone in patients with advanced non-small-cell lung cancer.
- Published in:
- Investigational New Drugs, 2020, v. 38, n. 5, p. 1588, doi. 10.1007/s10637-020-00930-5
- By:
- Publication type:
- Article
A Case Report of Successful Treatment With Crizotinib to Overcome Resistance to Osimertinib in an EGFR Mutated Non–Small-Cell Lung Cancer Patient Harboring an Acquired MET Exon 14 Mutation.
- Published in:
- Clinical Lung Cancer, 2022, v. 23, n. 2, p. e131, doi. 10.1016/j.cllc.2021.06.002
- By:
- Publication type:
- Article
Relevance of Detection of Mechanisms of Resistance to ALK Inhibitors in ALK-Rearranged NSCLC in Routine Practice.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Current and Former Smokers: Who Wants To Be Screened?
- Published in:
- 2018
- By:
- Publication type:
- journal article
Mutation of TP53 and alteration of p14(arf) expression in EGFR- and KRAS-mutated lung adenocarcinomas.
- Published in:
- 2014
- By:
- Publication type:
- journal article
Mutation of TP53 and Alteration of p14<sup>arf</sup> Expression in EGFR- and KRAS-Mutated Lung Adenocarcinomas.
- Published in:
- Clinical Lung Cancer, 2014, v. 15, n. 2, p. 124, doi. 10.1016/j.cllc.2013.08.003
- By:
- Publication type:
- Article
Histology... For Want of Anything Better?
- Published in:
- Oncology (08909091), 2009, v. 23, n. 13, p. 1140
- By:
- Publication type:
- Article
Transforming properties of MET receptor exon 14 skipping can be recapitulated by loss of the CBL ubiquitin ligase binding site.
- Published in:
- FEBS Letters, 2023, v. 597, n. 18, p. 2301, doi. 10.1002/1873-3468.14702
- By:
- Publication type:
- Article
Novel mutant-selective EGFR kinase inhibitors against EGFR T790M.
- Published in:
- Nature, 2009, v. 462, n. 7276, p. 1070, doi. 10.1038/nature08622
- By:
- Publication type:
- Article
EGFR and KRAS status of primary sarcomatoid carcinomas of the lung: Implications for anti-EGFR treatment of a rare lung malignancy.
- Published in:
- International Journal of Cancer, 2009, v. 125, n. 10, p. 2479, doi. 10.1002/ijc.24610
- By:
- Publication type:
- Article
ctDNA Dynamics, Prognostic Markers, and Mechanisms of Resistance in Tepotinib-treated MET exon 14 (METex14) Skipping NSCLC in the VISION Trial.
- Published in:
- Journal of Oncology Navigation & Survivorship, 2023, v. 14, n. 11, p. 352
- By:
- Publication type:
- Article
Histo-Molecular Factors of Response to Combined Chemotherapy and Immunotherapy in Non-Small Cell Lung Cancers.
- Published in:
- Targeted Oncology, 2023, v. 18, n. 6, p. 927, doi. 10.1007/s11523-023-01009-w
- By:
- Publication type:
- Article
Response to Capmatinib in a MET Fusion-positive Cholangiocarcinoma.
- Published in:
- Oncologist, 2023, v. 28, n. 1, p. 80, doi. 10.1093/oncolo/oyac194
- By:
- Publication type:
- Article
Exon 14 Deleted MET Receptor as a New Biomarker and Target in Cancers.
- Published in:
- 2017
- By:
- Publication type:
- journal article
A Randomized Phase III Study of Abemaciclib Versus Erlotinib in Patients with Stage IV Non-small Cell Lung Cancer With a Detectable KRAS Mutation Who Failed Prior Platinum-Based Therapy: JUNIPER.
- Published in:
- Frontiers in Oncology, 2020, v. 11, p. N.PAG, doi. 10.3389/fonc.2020.578756
- By:
- Publication type:
- Article
PEA3 transcription factors are downstream effectors of Met signaling involved in migration and invasiveness of Met-addicted tumor cells.
- Published in:
- Molecular Oncology, 2015, v. 9, n. 9, p. 1852, doi. 10.1016/j.molonc.2015.07.001
- By:
- Publication type:
- Article